APO Research
Talk to an analyst

APO RESEARCH · REPORT

mRNA Raw Enzyme

mRNA raw enzymes are key enzymes used in the synthesis of mRNA, catalyzing the synthesis of RNA from a DNA template in vitro or playing roles in mRNA modification and processing. The production process of mRNA raw enzymes typically includes several steps: cloning the gene encoding the target enzyme into an appropriate expression vector and expressing it in a suitable host cell (e.g., E. coli, yeast, or insect cells); large-scale culturing of the host cells expressing the target enzyme; extracting and purifying the target enzyme through cell lysis, centrifugation, chromatography, etc.; assessing the activity, purity, stability, and other quality parameters of the purified enzyme; and finally, lyophilizing the purified enzyme and packaging it into suitable product forms for downstream use.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

mRNA raw enzymes are key enzymes used in the synthesis of mRNA, catalyzing the synthesis of RNA from a DNA template in vitro or playing roles in mRNA modification and processing. The production process of mRNA raw enzymes typically includes several steps: cloning the gene encoding the target enzyme into an appropriate expression vector and expressing it in a suitable host cell (e.g., E. coli, yeast, or insect cells); large-scale culturing of the host cells expressing the target enzyme; extracting and purifying the target enzyme through cell lysis, centrifugation, chromatography, etc.; assessing the activity, purity, stability, and other quality parameters of the purified enzyme; and finally, lyophilizing the purified enzyme and packaging it into suitable product forms for downstream use.

mRNA was first discovered in 1961, but due to its low stability, the development of mRNA-based drugs progressed slowly. In recent years, with the continuous advancement of mRNA synthesis and delivery technologies, the stability and translation efficiency of mRNA have significantly improved, leading to rapid development in mRNA applications. As a highly promising pharmaceutical technology platform, mRNA is widely applied in areas such as infectious disease prevention, cancer immunotherapy, and protein replacement therapy. The COVID-19 pandemic in 2020 catalyzed the comprehensive development of the global vaccine industry, with mRNA vaccines gaining significant attention and recognition due to their short development cycle, fast production speed, and lack of genomic integration risks.

mRNA is a single-stranded ribonucleic acid transcribed from DNA, carrying genetic information that guides protein synthesis. mRNA transmits information from DNA to ribosomes, where it is translated into proteins, facilitating various life activities. Currently, most products on the market are mRNA vaccines (prophylactic vaccines). mRNA vaccines mimic the natural infection process of a virus in the body, effectively eliciting both humoral and cellular immunity, with high safety. They can bypass the constraints of strain or serotype acquisition, supporting the development of vaccines for specific antigens.

Due to its potential for preventing and treating various diseases, mRNA vaccines are set to replace traditional vaccines as a revolutionary platform, applicable to infectious disease vaccines, prophylactic cancer vaccines, and therapeutic vaccines. mRNA vaccines can induce T-cell immunity targeting specific immune goals more precisely. According to APO Research, mRNA vaccines are suitable for molecules with poor druggability. Many drugs have complex spatial structures, making synthesis difficult, while drugs produced by human cells are more effective. mRNA provides more possibilities for the clinical application of drugs with poor druggability. Additionally, the mRNA platform is flexible; simply changing the mRNA sequence can shift to new molecules and indications. Manufacturers can leverage the mRNA delivery systems and modification methods from previous products, effectively reducing development time and costs. Beyond vaccine applications, another vast market for mRNA is antibody drugs and other protein therapeutics. mRNA drugs can express antibodies or proteins in vivo, replacing the existing treatment methods of producing antibodies/protein drugs in vitro. mRNA drugs use human cells directly as bioreactors, avoiding concerns about correct spatial conformation and post-translational modifications of protein drugs, reducing the need for sequence optimization and complex modification and purification processes. Several mRNA replacement therapies are already in clinical trials.

Selected research

Market Outlook & Growth Opportunities

Global mRNA Raw Enzyme Market Outlook and Growth Opportunities 2026

27 December 2025204 pages

Choose your research edition.

Industry ResearchmRNA Raw Enzyme Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal mRNA Raw Enzyme Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal mRNA Raw Enzyme Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal mRNA Raw Enzyme Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal mRNA Raw Enzyme Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

mRNA raw enzymes are key enzymes used in the synthesis of mRNA, catalyzing the synthesis of RNA from a DNA template in vitro or playing roles in mRNA modification and processing. The production process of mRNA raw enzymes typically includes several steps: cloning the gene encoding the target enzyme into an appropriate expression vector and expressing it in a suitable host cell (e.g., E. coli, yeast, or insect cells); large-scale culturing of the host cells expressing the target enzyme; extracting and purifying the target enzyme through cell lysis, centrifugation, chromatography, etc.; assessing the activity, purity, stability, and other quality parameters of the purified enzyme; and finally, lyophilizing the purified enzyme and packaging it into suitable product forms for downstream use.

mRNA was first discovered in 1961, but due to its low stability, the development of mRNA-based drugs progressed slowly. In recent years, with the continuous advancement of mRNA synthesis and delivery technologies, the stability and translation efficiency of mRNA have significantly improved, leading to rapid development in mRNA applications. As a highly promising pharmaceutical technology platform, mRNA is widely applied in areas such as infectious disease prevention, cancer immunotherapy, and protein replacement therapy. The COVID-19 pandemic in 2020 catalyzed the comprehensive development of the global vaccine industry, with mRNA vaccines gaining significant attention and recognition due to their short development cycle, fast production speed, and lack of genomic integration risks.

mRNA is a single-stranded ribonucleic acid transcribed from DNA, carrying genetic information that guides protein synthesis. mRNA transmits information from DNA to ribosomes, where it is translated into proteins, facilitating various life activities. Currently, most products on the market are mRNA vaccines (prophylactic vaccines). mRNA vaccines mimic the natural infection process of a virus in the body, effectively eliciting both humoral and cellular immunity, with high safety. They can bypass the constraints of strain or serotype acquisition, supporting the development of vaccines for specific antigens.

Read the full market overview

Due to its potential for preventing and treating various diseases, mRNA vaccines are set to replace traditional vaccines as a revolutionary platform, applicable to infectious disease vaccines, prophylactic cancer vaccines, and therapeutic vaccines. mRNA vaccines can induce T-cell immunity targeting specific immune goals more precisely. According to APO Research, mRNA vaccines are suitable for molecules with poor druggability. Many drugs have complex spatial structures, making synthesis difficult, while drugs produced by human cells are more effective. mRNA provides more possibilities for the clinical application of drugs with poor druggability. Additionally, the mRNA platform is flexible; simply changing the mRNA sequence can shift to new molecules and indications. Manufacturers can leverage the mRNA delivery systems and modification methods from previous products, effectively reducing development time and costs. Beyond vaccine applications, another vast market for mRNA is antibody drugs and other protein therapeutics. mRNA drugs can express antibodies or proteins in vivo, replacing the existing treatment methods of producing antibodies/protein drugs in vitro. mRNA drugs use human cells directly as bioreactors, avoiding concerns about correct spatial conformation and post-translational modifications of protein drugs, reducing the need for sequence optimization and complex modification and purification processes. Several mRNA replacement therapies are already in clinical trials.

The global mRNA Raw Enzyme market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for mRNA Raw Enzyme is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for mRNA Raw Enzyme is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Asia Pacific market for mRNA Raw Enzyme is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the mRNA Raw Enzyme market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the mRNA Raw Enzyme market include Thermo Fisher, NEB, Merck, Aldevron, Roche CustomBiotech, Takara Bio Inc., Qiagen N.V., Promega and Novoprotein, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global mRNA Raw Enzyme market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of mRNA Raw Enzyme and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents mRNA Raw Enzyme revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global mRNA Raw Enzyme market.

mRNA Raw Enzyme Segment by Company

Thermo Fisher

NEB

Merck

Aldevron

Roche CustomBiotech

Takara Bio Inc.

Qiagen N.V.

Promega

Novoprotein

Alphazyme

LGC Biosearch Technologies

Jena Bioscience

Yeasen Biotechnology

Hongene Biotech

Enzo Biochem

Spindle (Applied DNA Sciences)

Vazyme

KACTUS

Hzymes Biotech

mRNA Raw Enzyme Segment by Type

Restriction Enzyme

RNA Polymerase

Capping Enzyme

Inorganic Pyrophosphatase

RNase Inhibitor

2'-O-Methyltransferase

Poly(A) Polymerase

DNase I

mRNA Raw Enzyme Segment by Application

Biopharmaceutical Companies

Academic and Research Institutes

mRNA Raw Enzyme Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global mRNA Raw Enzyme status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the mRNA Raw Enzyme key companies, revenue, market share, and recent developments.

3. To split the mRNA Raw Enzyme breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions mRNA Raw Enzyme market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify mRNA Raw Enzyme significant trends, drivers, influence factors in global and regions.

6. To analyze mRNA Raw Enzyme competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Raw Enzyme market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of mRNA Raw Enzyme and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Raw Enzyme.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global mRNA Raw Enzyme industry.

Chapter 3: Detailed analysis of mRNA Raw Enzyme company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of mRNA Raw Enzyme in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of mRNA Raw Enzyme in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. mRNA Raw Enzyme Industry Trends Table 2. mRNA Raw Enzyme Industry Drivers Table 3. mRNA Raw Enzyme Industry Opportunities and Challenges Table 4. mRNA Raw Enzyme Industry Restraints Table 5. Global mRNA Raw Enzyme Revenue by Company (US$ Million) & (2021-2026) Table 6. Global mRNA Raw Enzyme Revenue Share by Company (2021-2026) Table 7. Global mRNA Raw Enzyme Company Ranking, (2024-2026) & (US$ Million) Table 8. Global mRNA Raw Enzyme Key Company Manufacturing Base & Headquarters Table 9. Global mRNA Raw Enzyme Company, Product Type & Application Table 10. Global mRNA Raw Enzyme Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global mRNA Raw Enzyme by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Restriction Enzyme Table 15. Significant Companies of RNA Polymerase Table 16. Significant Companies of Capping Enzyme Table 17. Significant Companies of Inorganic Pyrophosphatase Table 18. Significant Companies of RNase Inhibitor Table 19. Significant Companies of 2'-O-Methyltransferase Table 20. Significant Companies of Poly(A) Polymerase Table 21. Significant Companies of DNase I Table 22. Global mRNA Raw Enzyme Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 23. Global mRNA Raw Enzyme Sales Value by Type (2021-2026) & (US$ Million) Table 24. Global mRNA Raw Enzyme Sales Value by Type (2027-2032) & (US$ Million) Table 25. Global mRNA Raw Enzyme Sales Value Share by Type (2021-2026) Table 26. Global mRNA Raw Enzyme Sales Value Share by Type (2027-2032) Table 27. Significant Companies of Biopharmaceutical Companies Table 28. Significant Companies of Academic and Research Institutes Table 29. Global mRNA Raw Enzyme Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global mRNA Raw Enzyme Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global mRNA Raw Enzyme Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global mRNA Raw Enzyme Sales Value Share by Application (2021-2026) Table 33. Global mRNA Raw Enzyme Sales Value Share by Application (2027-2032) Table 34. Global mRNA Raw Enzyme Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global mRNA Raw Enzyme Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global mRNA Raw Enzyme Sales Value Share by Region (2021-2026) Table 37. Global mRNA Raw Enzyme Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global mRNA Raw Enzyme Sales Value Share by Region (2027-2032) Table 39. Global mRNA Raw Enzyme Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global mRNA Raw Enzyme Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global mRNA Raw Enzyme Sales Value Market Share by Country (2021-2026) Table 42. Global mRNA Raw Enzyme Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global mRNA Raw Enzyme Sales Value Market Share by Country (2027-2032) Table 44. Thermo Fisher Company Information Table 45. Thermo Fisher Business Overview Table 46. Thermo Fisher mRNA Raw Enzyme Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Thermo Fisher mRNA Raw Enzyme Product Portfolio Table 48. Thermo Fisher Recent Development Table 49. NEB Company Information Table 50. NEB Business Overview Table 51. NEB mRNA Raw Enzyme Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. NEB mRNA Raw Enzyme Product Portfolio Table 53. NEB Recent Development Table 54. Merck Company Information Table 55. Merck Business Overview Table 56. Merck mRNA Raw Enzyme Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Merck mRNA Raw Enzyme Product Portfolio Table 58. Merck Recent Development Table 59. Aldevron Company Information Table 60. Aldevron Business Overview Table 61. Aldevron mRNA Raw Enzyme Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Aldevron mRNA Raw Enzyme Product Portfolio Table 63. Aldevron Recent Development Table 64. Roche CustomBiotech Company Information Table 65. Roche CustomBiotech Business Overview Table 66. Roche CustomBiotech mRNA Raw Enzyme Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Roche CustomBiotech mRNA Raw Enzyme Product Portfolio Table 68. Roche CustomBiotech Recent Development Table 69. Takara Bio Inc. Company Information Table 70. Takara Bio Inc. Business Overview Table 71. Takara Bio Inc. mRNA Raw Enzyme Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Takara Bio Inc. mRNA Raw Enzyme Product Portfolio Table 73. Takara Bio Inc. Recent Development Table 74. Qiagen N.V. Company Information Table 75. Qiagen N.V. Business Overview Table 76. Qiagen N.V. mRNA Raw Enzyme Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Qiagen N.V. mRNA Raw Enzyme Product Portfolio Table 78. Qiagen N.V. Recent Development Table 79. Promega Company Information Table 80. Promega Business Overview Table 81. Promega mRNA Raw Enzyme Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Promega mRNA Raw Enzyme Product Portfolio Table 83. Promega Recent Development Table 84. Novoprotein Company Information Table 85. Novoprotein Business Overview Table 86. Novoprotein mRNA Raw Enzyme Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Novoprotein mRNA Raw Enzyme Product Portfolio Table 88. Novoprotein Recent Development Table 89. Alphazyme Company Information Table 90. Alphazyme Business Overview Table 91. Alphazyme mRNA Raw Enzyme Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Alphazyme mRNA Raw Enzyme Product Portfolio Table 93. Alphazyme Recent Development Table 94. LGC Biosearch Technologies Company Information Table 95. LGC Biosearch Technologies Business Overview Table 96. LGC Biosearch Technologies mRNA Raw Enzyme Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. LGC Biosearch Technologies mRNA Raw Enzyme Product Portfolio Table 98. LGC Biosearch Technologies Recent Development Table 99. Jena Bioscience Company Information Table 100. Jena Bioscience Business Overview Table 101. Jena Bioscience mRNA Raw Enzyme Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Jena Bioscience mRNA Raw Enzyme Product Portfolio Table 103. Jena Bioscience Recent Development Table 104. Yeasen Biotechnology Company Information Table 105. Yeasen Biotechnology Business Overview Table 106. Yeasen Biotechnology mRNA Raw Enzyme Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Yeasen Biotechnology mRNA Raw Enzyme Product Portfolio Table 108. Yeasen Biotechnology Recent Development Table 109. Hongene Biotech Company Information Table 110. Hongene Biotech Business Overview Table 111. Hongene Biotech mRNA Raw Enzyme Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Hongene Biotech mRNA Raw Enzyme Product Portfolio Table 113. Hongene Biotech Recent Development Table 114. Enzo Biochem Company Information Table 115. Enzo Biochem Business Overview Table 116. Enzo Biochem mRNA Raw Enzyme Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Enzo Biochem mRNA Raw Enzyme Product Portfolio Table 118. Enzo Biochem Recent Development Table 119. Spindle (Applied DNA Sciences) Company Information Table 120. Spindle (Applied DNA Sciences) Business Overview Table 121. Spindle (Applied DNA Sciences) mRNA Raw Enzyme Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Spindle (Applied DNA Sciences) mRNA Raw Enzyme Product Portfolio Table 123. Spindle (Applied DNA Sciences) Recent Development Table 124. Vazyme Company Information Table 125. Vazyme Business Overview Table 126. Vazyme mRNA Raw Enzyme Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Vazyme mRNA Raw Enzyme Product Portfolio Table 128. Vazyme Recent Development Table 129. KACTUS Company Information Table 130. KACTUS Business Overview Table 131. KACTUS mRNA Raw Enzyme Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. KACTUS mRNA Raw Enzyme Product Portfolio Table 133. KACTUS Recent Development Table 134. Hzymes Biotech Company Information Table 135. Hzymes Biotech Business Overview Table 136. Hzymes Biotech mRNA Raw Enzyme Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Hzymes Biotech mRNA Raw Enzyme Product Portfolio Table 138. Hzymes Biotech Recent Development Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. mRNA Raw Enzyme Product Image Figure 2. Global mRNA Raw Enzyme Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global mRNA Raw Enzyme Market Size (2021-2032) & (US$ Million) Figure 4. Global mRNA Raw Enzyme Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Restriction Enzyme Image Figure 8. RNA Polymerase Image Figure 9. Capping Enzyme Image Figure 10. Inorganic Pyrophosphatase Image Figure 11. RNase Inhibitor Image Figure 12. 2'-O-Methyltransferase Image Figure 13. Poly(A) Polymerase Image Figure 14. DNase I Image Figure 15. Global mRNA Raw Enzyme Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global mRNA Raw Enzyme Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global mRNA Raw Enzyme Sales Value Share by Type (2021-2032) Figure 18. Biopharmaceutical Companies Image Figure 19. Academic and Research Institutes Image Figure 20. Global mRNA Raw Enzyme Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global mRNA Raw Enzyme Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global mRNA Raw Enzyme Sales Value Share by Application (2021-2032) Figure 23. Global mRNA Raw Enzyme Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global mRNA Raw Enzyme Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America mRNA Raw Enzyme Sales Value (2021-2032) & (US$ Million) Figure 26. North America mRNA Raw Enzyme Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe mRNA Raw Enzyme Sales Value (2021-2032) & (US$ Million) Figure 28. Europe mRNA Raw Enzyme Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific mRNA Raw Enzyme Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific mRNA Raw Enzyme Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America mRNA Raw Enzyme Sales Value (2021-2032) & (US$ Million) Figure 32. South America mRNA Raw Enzyme Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa mRNA Raw Enzyme Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa mRNA Raw Enzyme Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt mRNA Raw Enzyme Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • Restriction Enzyme
  • RNA Polymerase
  • Capping Enzyme
  • Inorganic Pyrophosphatase
  • RNase Inhibitor
  • 2'-O-Methyltransferase
  • Poly(A) Polymerase
  • DNase I
Applications
  • Biopharmaceutical Companies
  • Academic and Research Institutes
Companies covered
  • Thermo Fisher
  • NEB
  • Merck
  • Aldevron
  • Roche CustomBiotech
  • Takara Bio Inc.
  • Qiagen N.V.
  • Promega
  • Novoprotein
  • Alphazyme
  • LGC Biosearch Technologies
  • Jena Bioscience
  • Yeasen Biotechnology
  • Hongene Biotech
  • Enzo Biochem
  • Spindle (Applied DNA Sciences)
  • Vazyme
  • KACTUS
  • Hzymes Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global mRNA Raw Enzyme Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global mRNA Raw Enzyme Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 mRNA Raw Enzyme Market Dynamics
  1. 2.1 mRNA Raw Enzyme Industry Trends
  2. 2.2 mRNA Raw Enzyme Industry Drivers
  3. 2.3 mRNA Raw Enzyme Industry Opportunities and Challenges
  4. 2.4 mRNA Raw Enzyme Industry Restraints
3 mRNA Raw Enzyme Market by Company
  1. 3.1 Global mRNA Raw Enzyme Company Revenue Ranking in 2025
  2. 3.2 Global mRNA Raw Enzyme Revenue by Company (2021-2026)
  3. 3.3 Global mRNA Raw Enzyme Company Ranking (2024-2026)
  4. 3.4 Global mRNA Raw Enzyme Company Manufacturing Base and Headquarters
  5. 3.5 Global mRNA Raw Enzyme Company Product Type and Application
  6. 3.6 Global mRNA Raw Enzyme Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global mRNA Raw Enzyme Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 mRNA Raw Enzyme Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 mRNA Raw Enzyme Market by Type
  1. 4.1 mRNA Raw Enzyme Type Introduction
  2. 4.1.1 Restriction Enzyme
  3. 4.1.2 RNA Polymerase
  4. 4.1.3 Capping Enzyme
  5. 4.1.4 Inorganic Pyrophosphatase
  6. 4.1.5 RNase Inhibitor
  7. 4.1.6 2'-O-Methyltransferase
  8. 4.1.7 Poly(A) Polymerase
  9. 4.1.8 DNase I
  10. 4.2 Global mRNA Raw Enzyme Sales Value by Type
  11. 4.2.1 Global mRNA Raw Enzyme Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global mRNA Raw Enzyme Sales Value by Type (2021-2032)
  13. 4.2.3 Global mRNA Raw Enzyme Sales Value Share by Type (2021-2032)
5 mRNA Raw Enzyme Market by Application
  1. 5.1 mRNA Raw Enzyme Application Introduction
  2. 5.1.1 Biopharmaceutical Companies
  3. 5.1.2 Academic and Research Institutes
  4. 5.2 Global mRNA Raw Enzyme Sales Value by Application
  5. 5.2.1 Global mRNA Raw Enzyme Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global mRNA Raw Enzyme Sales Value by Application (2021-2032)
  7. 5.2.3 Global mRNA Raw Enzyme Sales Value Share by Application (2021-2032)
6 mRNA Raw Enzyme Regional Value Analysis
  1. 6.1 Global mRNA Raw Enzyme Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global mRNA Raw Enzyme Sales Value by Region (2021-2032)
  3. 6.2.1 Global mRNA Raw Enzyme Sales Value by Region: 2021-2026
  4. 6.2.2 Global mRNA Raw Enzyme Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America mRNA Raw Enzyme Sales Value (2021-2032)
  7. 6.3.2 North America mRNA Raw Enzyme Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe mRNA Raw Enzyme Sales Value (2021-2032)
  10. 6.4.2 Europe mRNA Raw Enzyme Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific mRNA Raw Enzyme Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific mRNA Raw Enzyme Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America mRNA Raw Enzyme Sales Value (2021-2032)
  16. 6.6.2 South America mRNA Raw Enzyme Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa mRNA Raw Enzyme Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa mRNA Raw Enzyme Sales Value Share by Country, 2025 VS 2032
7 mRNA Raw Enzyme Country-level Value Analysis
  1. 7.1 Global mRNA Raw Enzyme Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global mRNA Raw Enzyme Sales Value by Country (2021-2032)
  3. 7.2.1 Global mRNA Raw Enzyme Sales Value by Country (2021-2026)
  4. 7.2.2 Global mRNA Raw Enzyme Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt mRNA Raw Enzyme Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt mRNA Raw Enzyme Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt mRNA Raw Enzyme Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher
  2. 8.1.1 Thermo Fisher Company Information
  3. 8.1.2 Thermo Fisher Business Overview
  4. 8.1.3 Thermo Fisher mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher mRNA Raw Enzyme Product Portfolio
  6. 8.1.5 Thermo Fisher Recent Developments
  7. 8.2 NEB
  8. 8.2.1 NEB Company Information
  9. 8.2.2 NEB Business Overview
  10. 8.2.3 NEB mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  11. 8.2.4 NEB mRNA Raw Enzyme Product Portfolio
  12. 8.2.5 NEB Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck mRNA Raw Enzyme Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Aldevron
  20. 8.4.1 Aldevron Company Information
  21. 8.4.2 Aldevron Business Overview
  22. 8.4.3 Aldevron mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Aldevron mRNA Raw Enzyme Product Portfolio
  24. 8.4.5 Aldevron Recent Developments
  25. 8.5 Roche CustomBiotech
  26. 8.5.1 Roche CustomBiotech Company Information
  27. 8.5.2 Roche CustomBiotech Business Overview
  28. 8.5.3 Roche CustomBiotech mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche CustomBiotech mRNA Raw Enzyme Product Portfolio
  30. 8.5.5 Roche CustomBiotech Recent Developments
  31. 8.6 Takara Bio Inc.
  32. 8.6.1 Takara Bio Inc. Company Information
  33. 8.6.2 Takara Bio Inc. Business Overview
  34. 8.6.3 Takara Bio Inc. mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Takara Bio Inc. mRNA Raw Enzyme Product Portfolio
  36. 8.6.5 Takara Bio Inc. Recent Developments
  37. 8.7 Qiagen N.V.
  38. 8.7.1 Qiagen N.V. Company Information
  39. 8.7.2 Qiagen N.V. Business Overview
  40. 8.7.3 Qiagen N.V. mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Qiagen N.V. mRNA Raw Enzyme Product Portfolio
  42. 8.7.5 Qiagen N.V. Recent Developments
  43. 8.8 Promega
  44. 8.8.1 Promega Company Information
  45. 8.8.2 Promega Business Overview
  46. 8.8.3 Promega mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Promega mRNA Raw Enzyme Product Portfolio
  48. 8.8.5 Promega Recent Developments
  49. 8.9 Novoprotein
  50. 8.9.1 Novoprotein Company Information
  51. 8.9.2 Novoprotein Business Overview
  52. 8.9.3 Novoprotein mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novoprotein mRNA Raw Enzyme Product Portfolio
  54. 8.9.5 Novoprotein Recent Developments
  55. 8.10 Alphazyme
  56. 8.10.1 Alphazyme Company Information
  57. 8.10.2 Alphazyme Business Overview
  58. 8.10.3 Alphazyme mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Alphazyme mRNA Raw Enzyme Product Portfolio
  60. 8.10.5 Alphazyme Recent Developments
  61. 8.11 LGC Biosearch Technologies
  62. 8.11.1 LGC Biosearch Technologies Company Information
  63. 8.11.2 LGC Biosearch Technologies Business Overview
  64. 8.11.3 LGC Biosearch Technologies mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  65. 8.11.4 LGC Biosearch Technologies mRNA Raw Enzyme Product Portfolio
  66. 8.11.5 LGC Biosearch Technologies Recent Developments
  67. 8.12 Jena Bioscience
  68. 8.12.1 Jena Bioscience Company Information
  69. 8.12.2 Jena Bioscience Business Overview
  70. 8.12.3 Jena Bioscience mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Jena Bioscience mRNA Raw Enzyme Product Portfolio
  72. 8.12.5 Jena Bioscience Recent Developments
  73. 8.13 Yeasen Biotechnology
  74. 8.13.1 Yeasen Biotechnology Company Information
  75. 8.13.2 Yeasen Biotechnology Business Overview
  76. 8.13.3 Yeasen Biotechnology mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Yeasen Biotechnology mRNA Raw Enzyme Product Portfolio
  78. 8.13.5 Yeasen Biotechnology Recent Developments
  79. 8.14 Hongene Biotech
  80. 8.14.1 Hongene Biotech Company Information
  81. 8.14.2 Hongene Biotech Business Overview
  82. 8.14.3 Hongene Biotech mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Hongene Biotech mRNA Raw Enzyme Product Portfolio
  84. 8.14.5 Hongene Biotech Recent Developments
  85. 8.15 Enzo Biochem
  86. 8.15.1 Enzo Biochem Company Information
  87. 8.15.2 Enzo Biochem Business Overview
  88. 8.15.3 Enzo Biochem mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Enzo Biochem mRNA Raw Enzyme Product Portfolio
  90. 8.15.5 Enzo Biochem Recent Developments
  91. 8.16 Spindle (Applied DNA Sciences)
  92. 8.16.1 Spindle (Applied DNA Sciences) Company Information
  93. 8.16.2 Spindle (Applied DNA Sciences) Business Overview
  94. 8.16.3 Spindle (Applied DNA Sciences) mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Spindle (Applied DNA Sciences) mRNA Raw Enzyme Product Portfolio
  96. 8.16.5 Spindle (Applied DNA Sciences) Recent Developments
  97. 8.17 Vazyme
  98. 8.17.1 Vazyme Company Information
  99. 8.17.2 Vazyme Business Overview
  100. 8.17.3 Vazyme mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Vazyme mRNA Raw Enzyme Product Portfolio
  102. 8.17.5 Vazyme Recent Developments
  103. 8.18 KACTUS
  104. 8.18.1 KACTUS Company Information
  105. 8.18.2 KACTUS Business Overview
  106. 8.18.3 KACTUS mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  107. 8.18.4 KACTUS mRNA Raw Enzyme Product Portfolio
  108. 8.18.5 KACTUS Recent Developments
  109. 8.19 Hzymes Biotech
  110. 8.19.1 Hzymes Biotech Company Information
  111. 8.19.2 Hzymes Biotech Business Overview
  112. 8.19.3 Hzymes Biotech mRNA Raw Enzyme Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Hzymes Biotech mRNA Raw Enzyme Product Portfolio
  114. 8.19.5 Hzymes Biotech Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst